U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H19N3O.ClH
Molecular Weight 329.824
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FABESETRON HYDROCHLORIDE

SMILES

Cl.CC1=C(C[C@H]2CCC3=C(C)C4=C(C=CC=C4)N3C2=O)N=CN1

InChI

InChIKey=POKFYJWUPWZYQV-BTQNPOSSSA-N
InChI=1S/C18H19N3O.ClH/c1-11-14-5-3-4-6-17(14)21-16(11)8-7-13(18(21)22)9-15-12(2)19-10-20-15;/h3-6,10,13H,7-9H2,1-2H3,(H,19,20);1H/t13-;/m1./s1

HIDE SMILES / InChI

Description

Fabesetron is a dual 5HT3 and 5HT4 receptors antagonist that was developed in Japan for the treatment of chemotherapy-induced emesis and gastrointestinal disorders. The development of the drug was terminated in phase II.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
8.84 null [pIC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Unknown
Primary
Unknown
Secondary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
The effect of fabesteron on short-circuit current was investigated using submucosa-mucosa sheets of guinea-pig distal colon. The drug at 10(-9) M suppressed the 5-HT-evoked response to 69% of control.